| Species Reactivity | Human |
| Clone | CD79b/5C7 |
| Source/Isotype | Human IgG1(hole/knob), Kappa |
| Application | / |
| Specificity | Detects CLEC5A、CD79B |
| Gene | CLEC5A&CD79B |
| Other Names | CLEC5A: CLECSF5, MDL-1, MDL1 CD79B: AGM6, B29, IGB, Igbeta |
| Gene ID | CLEC5A: 23601 (Human) CD79B: 974 (Human) |
| Background | CLEC5A, as a member of the C-type lectin domain family, plays a dual role in disease: as a tumor suppressor in osteosarcoma, reducing metastatic capacity by inhibiting the calcineurin/NFATC1 pathway; While in sepsis and bacterial pneumonia, the upregulation of endothelial CLEC5A expression can disrupt vascular barrier function, exacerbate lung injury, and become a potential therapeutic target. CD79B, a key component of the b-cell receptor complex, is highly expressed in > 95% of diffuse large b-cell lymphomas (DLBCL) , and its aberrant activation can drive b-cell malignancy proliferation. Given the contradictory role of Clec5a in tumor suppression and inflammation regulation, and the specific expression of CD79B in b-cell malignancies, it is important to understand the role of CLEC5A and CD79B in b-cell malignancies, the development of Anti-CLEC5A × CD79B bispecific monoclonal antibody is expected to provide a novel therapeutic strategy for b-cell malignancies such as DLBCL by simultaneously blocking tumor proliferation signaling and inflammatory pathways. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | CD79b/5C7 |
| Source/Isotype | Human IgG1(hole/knob), Kappa |
| Application | / |
| Specificity | Detects CLEC5A、CD79B |
| Gene | CLEC5A&CD79B |
| Other Names | CLEC5A: CLECSF5, MDL-1, MDL1 CD79B: AGM6, B29, IGB, Igbeta |
| Gene ID | CLEC5A: 23601 (Human) CD79B: 974 (Human) |
| Background | CLEC5A, as a member of the C-type lectin domain family, plays a dual role in disease: as a tumor suppressor in osteosarcoma, reducing metastatic capacity by inhibiting the calcineurin/NFATC1 pathway; While in sepsis and bacterial pneumonia, the upregulation of endothelial CLEC5A expression can disrupt vascular barrier function, exacerbate lung injury, and become a potential therapeutic target. CD79B, a key component of the b-cell receptor complex, is highly expressed in > 95% of diffuse large b-cell lymphomas (DLBCL) , and its aberrant activation can drive b-cell malignancy proliferation. Given the contradictory role of Clec5a in tumor suppression and inflammation regulation, and the specific expression of CD79B in b-cell malignancies, it is important to understand the role of CLEC5A and CD79B in b-cell malignancies, the development of Anti-CLEC5A × CD79B bispecific monoclonal antibody is expected to provide a novel therapeutic strategy for b-cell malignancies such as DLBCL by simultaneously blocking tumor proliferation signaling and inflammatory pathways. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
